Targeted TFO delivery to hepatic stellate cells

Area of Science:

• Molecular Biology
• Gene Therapy
• Drug Delivery

Background:

• Triplex-forming oligonucleotides (TFOs) offer an antigene gene regulation strategy by targeting genomic DNA.
• In vivo delivery of TFOs to target cells remains a significant challenge for therapeutic applications.
• Previous conjugation strategies using cholesterol or mannose-6-phosphate-bovine serum albumin (M6P-BSA) faced limitations in targeted delivery and immunogenicity.

Purpose of the Study:

• To enhance the efficacy of TFOs for liver fibrosis treatment.
• To develop a TFO delivery system with improved targeting to hepatic stellate cells (HSCs).
• To create a TFO conjugate with reduced immunogenicity for antifibrotic therapy.

Main Methods:

• Conjugation of TFOs to mannose-6-phosphate-N-(2-hydroxypropyl)methacrylamide (M6P-HPMA) copolymer.
• Evaluation of TFO conjugate delivery to HSCs.
• Assessment of the antifibrotic potential by measuring collagen synthesis inhibition.
• Analysis of the immunogenicity of the M6P-HPMA conjugated TFOs.

Main Results:

• Conjugation of TFOs to M6P-HPMA significantly enhanced TFO delivery to HSCs.
• The M6P-HPMA-TFO conjugate demonstrated potential in treating liver fibrosis by inhibiting collagen synthesis.
• The M6P-HPMA copolymer exhibited negligible immunogenicity, unlike previous BSA conjugates.

Conclusions:

• M6P-HPMA-TFO conjugates represent a promising strategy for targeted delivery of TFOs to HSCs.
• This approach offers a more effective and safer therapeutic candidate for liver fibrosis compared to previous methods.
• The low immunogenicity of HPMA makes it a suitable carrier for antifibrotic TFO-based therapies.